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According to their disease-causing mechanism, many of the CF mutations can be
grouped in one of ﬁve mutation classes. These partially explain the heterogeneous
presentation of CF. Several studies have demonstrated that patients having at least
one mutation of class 4 or 5, usually present with a milder phenotype. We wanted
to compare disease severity and, especially, treatment burden between these patients
and subjects with two class 1, 2 or 3 mutations. Therefore, we included all
CF patients enrolled in the 2010 database of the Belgian CF Registry who could
be assigned to one of these two cohorts.
271 children and 335 adults with 2 known class 1/2/3 mutations were included,
plus 42 children and 49 adults with at least one class 4/5 mutation. In both age
categories mean sweat chloride was signiﬁcantly lower and age at diagnosis was
higher in class 4/5 patients. Pancreatic insufﬁciency, chronic Pseudomonas infection
and CF related diabetes were less common. Mean FEV1 was lower in adults with
class 4/5 mutations. Independent of age, class 4/5 patients had a lower mean number
of clinic visits, days in hospital, days with intravenous antibiotics; a lower proportion
used rhDNASe, mucolytics, oral or inhaled antibiotics, azithromycin, and inhaled
corticosteroids.
This study conﬁrms the milder phenotype seen in patients with CF and at least
one class 4 or 5 mutation. In addition, we demonstrate their signiﬁcantly lower
treatment burden compared to patients who have two class 1/2/3 mutations. These
ﬁndings contribute to providing better individual counseling at time of diagnosis
for patients with CF.
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More and more countries are implementing newborn screening (NBS) for CF. Early diagnosis via
NBS may inﬂuence the genotype distribution and clinical characteristics of patients diagnosed with
CF.
Objectives and Methods: To compare the demography and clinical characteristics of children with
CF younger than 8 years included in 2011 in national registries of countries with (France, Australia)
and without (Belgium, the Netherlands, Sweden) a national NBS program. To avoid inﬂuence of
regional screening pilot projects, only patients not diagnosed by NBS were included in the latter
countries.
Results: See the table.
Table: Main results
France Australia Belgium Netherlands Sweden
n (%)/total n in registry 1289/5993
(21.5%)
752/3131
(24.0%)
129/1551
(11.2%)
175/1374
(12.7%)
95/493
(19.3%)
Median (IQR) age (yr) 4.3
(2.3−6.2)
4.3
(2.4−6.1)
4.6
(2.3−6.5)
4.7
(3.2−5.8)
3.8
(2.4−5.7)
Median (IQR) age at diagn. (months) 1.1
(0.8−1.5)
1.0
(0.6−1.7)
2.4
(0.4−9.1)
3.6
(1.2−12.0)
5.5
(2.8−15.8)
Pancreatic insufﬁciency (PI) (%) 81.5
(79.3−83.6)
83.1
(80.2−85.8)
93.0
(87.2−96.8)
89.1
(83.6−93.0)
93.7
(86.8−97.6)
% with 2 CFTR disease causing
mut. a
78.4
(76.2−80.7)
93.9
(91.3−95.5)
84.5
(77.1−90.3)
89.1
(83.6−93.0)
89.5
(81.5−94.8)
% with sweat Cl 60mmol/L 15.0
(13.1−17.1)
12.5
(9.6−15.9)
2.7
(0.6−2.7)
6.4
(2.4−13.4)
3.3
(0.7−9.4)
% with sweat Cl 60mmol/L &
2 CFTR dis. causing mut. a
9.0
(7.4−10.6)
6.8
(4.1−10.8)
5.4
(2.2−10.8)
4.6
(2.2−8.9)
1.0
(0.0−6.4)
Proportions are expressed as % (95% conﬁdence interval).
a 2 CFTR disease causing mutations according to CFRT2 project.
NBS allowed establishing the diagnosis before the age of 2 months. The proportion of children
younger than 8 yrs was highest in national registries with NBS and the occurrence of PI was lower.
The proportion of young subjects with 2 CFTR disease causing mutations was lower in France but
not in Australia. The proportion of subjects with sweat chloride below 60 mEq/l or less than 2 disease
causing mutations was highest in France.
Conclusion: NBS does change the characteristics of young children included in CF registries. The
effect also reﬂects the screening strategy used.
WS4.3 Modeling airway infections in cystic ﬁbrosis
A.M. Granchelli1, F.R. Adler2,3, R.H. Keogh4, C. Kartsonaki5, M. Deschazer1,
D.R. Cox6, T. Liou7. 1University of Utah, Internal Medicine, Salt Lake City, United
States; 2University of Utah, Math, Salt Lake City, United States; 3University of
Utah, Biology, Salt Lake City, United States; 4London School of Hygiene and
Tropical Medicine, Medical Statistics, London, United Kingdom; 5Nufﬁeld College,
Statistics, Oxford, United Kingdom; 6Nufﬁeld College, Statistics, Oxford, United
States; 7University of Utah, Salt Lake City, United States
Objective: Cystic ﬁbrosis (CF) patients appear to demonstrate a temporal pro-
gression of airway infections. The study goal was to understand this pattern by
distinguishing the effects of age, clinical status and infections.
Methods: We used data from the CF Foundation Patient Registry (CFFPR) for
2003–2011. We initially evaluated confounding effects of age, year of database entry
and number of samples per patient. We applied generalized linear modeling on the
eight most common infections, namely methicillin sensitive Staphylococcus aureus
(MSSA),methicillin resistant S aureus (MRSA), Burkholderia cepacia, Pseudomonas
aeruginosa, Alcaligenes xylosoxidans, Candida species, Aspergillus species and
Stenotrophomonas maltophilia.We modeled future from current status of infection,
attempting to distinguish direct effects of infections from indirect effects mediated
through clinical covariates.
Results: We used 1,045,241 cultures from 28,426 patients. Strong interactions
appear to exist between speciﬁc infections. MSSA has a negative while MRSA
has a positive association on development of future infection with P aeruginosa.
P aeruginosa is negatively associated with future B cepacia and S maltophilia
infections. Candida and Aspergillus variably have positive, negative and null
associations with other infections.
Conclusions: Infections in CF do not follow a simple or stereotyped temporal
progression. However, the direct effects of current on future infections can be
accurately demonstrated. Understanding these effects may facilitate prediction of
future health outcomes and identify transitions between infections as potential
targets of intervention.
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Background: The prevalence of nontuberculous mycobacteria (NTM) among CF patients, while
frequently described as rising, also exhibits considerable regional differences. The prevalence in
Scandinavia has not previously been reported.
Methods: All CF patients in Denmark, Sweden and Norway were included in the study. Microbiolog-
ical data were collected from each of the 8 CF centres for the period 2000–2012. While variable over
time and between centres, all microbiological procedures were performed according to standardised
protocols, including pre-treatment, use of solid and liquid media and molecular diagnostics. Clinical
data were extracted from patient ﬁles and national registries.
Results: In 2000–2012, Scandinavia had an average CF population of 1,294. NTM was cultured
1,187 times from 162 CF patients (12%). M. abscessus complex (MABSC) was the most common
NTM (56% of patients), followed by M. avium complex (MAC) (48% of patients). 38% had between
2−4 positive cultures and 40% had 5 positive cultures. The median age was 19 and the male/female
ratio was 1.22. In 118/162 patients from whom clinical data was available from the time of ﬁrst NTM,
median FEV1 of predicted was 75%; 45% had a concurrent chronic infection with other bacteria, most
frequently with P. aeruginosa (34%) and 19/70 (27%) received azithromycin treatment. The annual
NTM incidence increased from an average of 8/1,000 in 2000–2006 to 13/1,000 in 2006–2012. Only
2 CF centres reported changes in screening policy.
Conclusion: The annual incidence of NTM has increased in Scandinavia between 2000–2012 and
presently 1 in 9 CF patients have been NTM culture positive at least once. The study is ongoing.
